Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Daiichi Sankyo
US Department of Justice
Covington
Dow
Julphar
QuintilesIMS
Boehringer Ingelheim
Citi
Chubb

Generated: February 24, 2018

DrugPatentWatch Database Preview

Bismuth subcitrate potassium; metronidazole; tetracycline - Generic Drug Details

« Back to Dashboard

What are the generic sources for bismuth subcitrate potassium; metronidazole; tetracycline and what is the scope of bismuth subcitrate potassium; metronidazole; tetracycline freedom to operate?

Bismuth subcitrate potassium; metronidazole; tetracycline
is the generic ingredient in one branded drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bismuth subcitrate potassium; metronidazole; tetracycline has thirty-two patent family members in twenty-four countries.

There are twenty-one drug master file entries for bismuth subcitrate potassium; metronidazole; tetracycline. Two suppliers are listed for this compound.
Summary for bismuth subcitrate potassium; metronidazole; tetracycline
Pharmacology for bismuth subcitrate potassium; metronidazole; tetracycline

US Patents and Regulatory Information for bismuth subcitrate potassium; metronidazole; tetracycline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for bismuth subcitrate potassium; metronidazole; tetracycline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for bismuth subcitrate potassium; metronidazole; tetracycline

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Chubb
AstraZeneca
Chinese Patent Office
Colorcon
Express Scripts
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot